These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38780418)
1. Tuning Recombinant Perlecan Domain V to Regulate Angiogenic Growth Factors and Enhance Endothelialization of Electrospun Silk Vascular Grafts. Jiang S; Yang N; Tan RP; Moh ESX; Fu L; Packer NH; Whitelock JM; Wise SG; Rnjak-Kovacina J; Lord MS Adv Healthc Mater; 2024 May; ():e2400855. PubMed ID: 38780418 [TBL] [Abstract][Full Text] [Related]
2. Biomimetic silk biomaterials: Perlecan-functionalized silk fibroin for use in blood-contacting devices. Lau K; Waterhouse A; Akhavan B; Gao L; Kim HN; Tang F; Whitelock JM; Bilek MM; Lord MS; Rnjak-Kovacina J Acta Biomater; 2021 Sep; 132():162-175. PubMed ID: 33588126 [TBL] [Abstract][Full Text] [Related]
3. Recombinant perlecan domain V covalently immobilized on silk biomaterials via plasma immersion ion implantation supports the formation of functional endothelium. Lau K; Fu L; Zhang A; Akhavan B; Whitelock J; Bilek MM; Lord MS; Rnjak-Kovacina J J Biomed Mater Res A; 2023 Jun; 111(6):825-839. PubMed ID: 36897070 [TBL] [Abstract][Full Text] [Related]
4. A Biomimetic Approach toward Enhancing Angiogenesis: Recombinantly Expressed Domain V of Human Perlecan Is a Bioactive Molecule That Promotes Angiogenesis and Vascularization of Implanted Biomaterials. Lin X; Tang F; Jiang S; Khamis H; Bongers A; Whitelock JM; Lord MS; Rnjak-Kovacina J Adv Sci (Weinh); 2020 Sep; 7(17):2000900. PubMed ID: 32995122 [TBL] [Abstract][Full Text] [Related]
5. Silk biomaterials functionalized with recombinant domain V of human perlecan modulate endothelial cell and platelet interactions for vascular applications. Rnjak-Kovacina J; Tang F; Whitelock JM; Lord MS Colloids Surf B Biointerfaces; 2016 Dec; 148():130-138. PubMed ID: 27591944 [TBL] [Abstract][Full Text] [Related]
6. Engineered short forms of perlecan enhance angiogenesis by potentiating growth factor signalling. Kim HN; Elgundi Z; Lin X; Fu L; Tang F; Moh ESX; Jung M; Chandrasekar K; Bartlett-Tomasetig F; Foster C; Packer NH; Whitelock JM; Rnjak-Kovacina J; Lord MS J Control Release; 2023 Oct; 362():184-196. PubMed ID: 37648081 [TBL] [Abstract][Full Text] [Related]
7. Effect of Recombinant Human Perlecan Domain V Tethering Method on Protein Orientation and Blood Contacting Activity on Polyvinyl Chloride. Chandrasekar K; Farrugia BL; Johnson L; Marks D; Irving D; Elgundi Z; Lau K; Kim HN; Rnjak-Kovacina J; Bilek MM; Whitelock JM; Lord MS Adv Healthc Mater; 2021 Jul; 10(14):e2100388. PubMed ID: 33890424 [TBL] [Abstract][Full Text] [Related]
8. The modulation of platelet and endothelial cell adhesion to vascular graft materials by perlecan. Lord MS; Yu W; Cheng B; Simmons A; Poole-Warren L; Whitelock JM Biomaterials; 2009 Oct; 30(28):4898-906. PubMed ID: 19540587 [TBL] [Abstract][Full Text] [Related]
9. The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling. Lord MS; Chuang CY; Melrose J; Davies MJ; Iozzo RV; Whitelock JM Matrix Biol; 2014 Apr; 35():112-22. PubMed ID: 24509440 [TBL] [Abstract][Full Text] [Related]
10. Recombinant Domain V of Human Perlecan Is a Bioactive Vascular Proteoglycan. Rnjak-Kovacina J; Tang F; Lin X; Whitelock JM; Lord MS Biotechnol J; 2017 Dec; 12(12):. PubMed ID: 28846206 [TBL] [Abstract][Full Text] [Related]
11. Surface Biofunctionalization of Silk Biomaterials Using Dityrosine Cross-Linking. Karimi F; Lau K; Kim HN; Och Z; Lim KS; Whitelock J; Lord M; Rnjak-Kovacina J ACS Appl Mater Interfaces; 2022 Jul; 14(28):31551-31566. PubMed ID: 35793155 [TBL] [Abstract][Full Text] [Related]
12. Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors. Smith SM; West LA; Govindraj P; Zhang X; Ornitz DM; Hassell JR Matrix Biol; 2007 Apr; 26(3):175-84. PubMed ID: 17169545 [TBL] [Abstract][Full Text] [Related]
13. Ablation of Perlecan Domain 1 Heparan Sulfate Reduces Progressive Cartilage Degradation, Synovitis, and Osteophyte Size in a Preclinical Model of Posttraumatic Osteoarthritis. Shu CC; Jackson MT; Smith MM; Smith SM; Penm S; Lord MS; Whitelock JM; Little CB; Melrose J Arthritis Rheumatol; 2016 Apr; 68(4):868-79. PubMed ID: 26636652 [TBL] [Abstract][Full Text] [Related]
14. Insight on the endothelialization of small silk-based tissue-engineered vascular grafts. Cordelle J; Mantero S Int J Artif Organs; 2020 Oct; 43(10):631-644. PubMed ID: 32148174 [TBL] [Abstract][Full Text] [Related]
15. Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury. Gotha L; Lim SY; Osherov AB; Wolff R; Qiang B; Erlich I; Nili N; Pillarisetti S; Chang YT; Tran PK; Tryggvason K; Hedin U; Tran-Lundmark K; Advani SL; Gilbert RE; Strauss BH Am J Physiol Heart Circ Physiol; 2014 Aug; 307(3):H337-45. PubMed ID: 24858854 [TBL] [Abstract][Full Text] [Related]
16. Perlecan heparan sulfate proteoglycan is a critical determinant of angiogenesis in response to mouse hind-limb ischemia. Qiang B; Lim SY; Lekas M; Kuliszewski MA; Wolff R; Osherov AB; Rudenko D; Leong-Poi H; Noyan H; Husain M; Tran K; Tryggvason K; Hedin U; Tran-Lundmark K; Strauss BH Can J Cardiol; 2014 Nov; 30(11):1444-51. PubMed ID: 25249499 [TBL] [Abstract][Full Text] [Related]
17. A simply prepared small-diameter artificial blood vessel that promotes in situ endothelialization. Guo HF; Dai WW; Qian DH; Qin ZX; Lei Y; Hou XY; Wen C Acta Biomater; 2017 May; 54():107-116. PubMed ID: 28238915 [TBL] [Abstract][Full Text] [Related]